Overview

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The main objective of the current trial is to investigate safety, tolerability and pharmacokinetics of BI 113608 in COPD patients with symptoms of chronic bronchitis.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim